{"": [137, 2142, 0], "1. Introduction": [2143, 6048, 0], "Remdesivir": [6860, 11620, 0], "Paxlovid": [11621, 12575, 0], "Molnupiravir": [12576, 13950, 0], "2.1.1. Treatments Targeted toward Viral Replication": [6807, 13950, 1], "Bamlanivimab and Etesevimab": [14712, 16428, 0], "Caririvimab and Imdevimab": [16429, 18048, 0], "Sotrovimab": [18049, 19126, 0], "Bebtelovimab": [19127, 21863, 0], "2.1.2. Direct SARS-CoV-2-Neutralizing Monoclonal Antibodies": [13951, 21863, 1], "2.1. Antiviral Therapies": [6781, 21863, 1], "2.2.1. Glucocorticoids": [21897, 26909, 0], "2.2.2. Janus Kinase Inhibitors": [26910, 29601, 0], "2.2.3. Interleukine-6 Receptor Inhibitors": [29602, 33444, 0], "2.2. Immunomodulatory Therapies": [21864, 33444, 1], "2. Clinical Trials of Therapeutics for COVID-19 Pneumonia": [6049, 33444, 1], "3. Conclusions": [33445, 38314, 0]}